FYI | Apr 17 2019
By Pitt Street Research
Anatara Lifesciences: Interview With CEO Steve Lydeamore
Stuart Roberts of Pitt Street Research recently sat down with Steve Lydeamore, CEO of Anatara Lifesciences ((ANR)) to talk about the path to market for the company's new dietary supplement product, called GaRP.
Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.
Watch the interview through the following link: https://www.pittstreetresearch.com/anatara
FNArena is a partner in distribution for Pitt Street Research. See also: https://www.fnarena.com/index.php/pitt-street-research/
Find out why FNArena subscribers like the service so much: "Your Feedback (Thank You)" – Warning this story contains unashamedly positive feedback on the service provided.
FNArena is proud about its track record and past achievements: Ten Years On